Trust Signals
All claims on this page are graded by evidence type. Mechanism claims backed only by cell or animal data are labeled as such and never presented with the same confidence as human trial findings. No statistics are cited unless traceable to a real named source. Where human data do not exist, this page says so plainly.
Key Takeaways
- KPV is a three-amino-acid fragment (Lys-Pro-Val) of alpha-MSH with a molecular weight of approximately 327.4 Da in its free acid form, giving it unusually rapid tissue penetration relative to larger peptides.
- Its primary documented mechanism is inhibition of NF-kB nuclear translocation in intestinal epithelial and immune cells, confirmed in multiple rodent colitis models (Dalmasso et al., 2008, Gastroenterology).
- No Phase 2 or Phase 3 human RCT has been completed for subcutaneous KPV injection; all dosing protocols currently in circulation are extrapolated from animal data or anecdote.
- Bacteriostatic water is required for reconstitution, not plain sterile water, because it provides a 28-day antimicrobial window from benzyl alcohol; plain sterile water offers no such protection.
- For gut-targeted applications, preclinical evidence actually favors oral nanoparticle delivery over subcutaneous injection; the injection route is not self-evidently optimal for this peptide.
What Is KPV Peptide Injection and Should You Use It?
KPV peptide injection is a subcutaneous research administration of the tripeptide Lys-Pro-Val, a C-terminal fragment of the endogenous anti-inflammatory hormone alpha-MSH. Preclinical evidence for anti-inflammatory and gut-mucosal effects is mechanistically solid but limited to animal and cell models. There are no published human RCTs supporting injection use. Anyone considering it takes on meaningful uncertainty.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is KPV and what does the injection form do?
- Evidence ledger: what the science actually shows
- Mechanism with numbers: how KPV works at the molecular level
- What most pages get wrong about KPV injectable peptide
- Reconstitution: step-by-step math
- KPV peptide injection benefits: honest summary
- KPV vs. alternatives: head-to-head table
- Operational guide: injection technique and site rotation
- Label literacy: how to read a KPV COA
- Side effects and contraindications
- FAQ
- Sources
What Is KPV and What Does the Injectable Form Do?
KPV (Lysine-Proline-Valine) is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). The full 13-amino-acid alpha-MSH hormone is produced endogenously from proopiomelanocortin (POMC) cleavage. Researchers isolated KPV as the minimal fragment retaining the anti-inflammatory activity of the parent hormone. Unlike large peptides, its small size means it crosses some barriers more readily, but it also degrades faster in serum. The injectable form delivers KPV systemically, bypassing first-pass gastrointestinal breakdown that would occur with unprotected oral dosing.
Evidence Ledger: What the Science Actually Shows
| Claim | Best Evidence Type | Key Reference | Effect Direction | Confidence |
|---|---|---|---|---|
| KPV reduces NF-kB activation in intestinal epithelial cells | In vitro cell study | Dalmasso et al., Gastroenterology 2008 | Positive (reduction) | Moderate (cell only) |
| KPV reduces colitis severity in mouse models | Animal (rodent) | Dalmasso et al., Gastroenterology 2008 | Positive | Moderate (animal) |
| Oral nanoparticle KPV improves murine colitis | Animal (rodent) | Laroui et al., Gastroenterology 2010 | Positive | Moderate (animal, different route) |
| KPV binds MC1R and MC3R melanocortin receptors | Receptor binding assay | Brzoska et al., J Invest Dermatol 2008 | Confirmed binding | High (mechanism confirmed) |
| Subcutaneous KPV injection improves inflammation in humans | Human RCT | None identified | Unknown | Very Low (no human trial) |
| KPV reduces wound inflammation in skin | Animal / in vitro | Brzoska et al., J Invest Dermatol 2008 | Positive | Low (animal/cell only) |
| KPV is safe for repeated human injection | Human safety data | None identified | Unknown | Very Low |
Mechanism With Numbers: How KPV Works at the Molecular Level
KPV acts through two confirmed receptor targets: melanocortin receptor 1 (MC1R), expressed on keratinocytes, macrophages, and mast cells, and MC3R, expressed on immune and gut epithelial cells. Binding at these receptors increases intracellular cyclic AMP, which activates protein kinase A. PKA phosphorylates and sequesters IkB kinase, preventing degradation of the inhibitory protein IkB-alpha. When IkB-alpha remains intact, it holds NF-kB in the cytoplasm rather than allowing nuclear translocation.
In the Dalmasso et al. 2008 Gastroenterology paper, KPV at concentrations in the nanomolar range reduced NF-kB-driven transcription and lowered secretion of TNF-alpha, IL-6, and IL-1beta in stimulated Caco-2 intestinal epithelial cells. In the colitis mouse model from the same study, intrarectal KPV reduced histological colitis scores. The MW of 327.4 Da for the tripeptide free acid allows paracellular and transcellular penetration in inflamed epithelium more readily than peptides above 500 Da.
What this does NOT prove: nanomolar efficacy in a cell bath does not translate to an effective systemic injection dose in a human. The concentration reaching the colonic mucosa after a subcutaneous injection depends on bioavailability, plasma half-life (not formally published for KPV in humans), and tissue distribution, none of which are characterized in human data.
What Most Pages Get Wrong About KPV Injectable Peptide
The most common error is presenting the injection route as obviously correct for gut inflammation, when the preclinical evidence base is actually stronger for local delivery. The Laroui et al. 2010 Gastroenterology study showing meaningful benefit used orally delivered KPV loaded into hydrogel nanoparticles targeting colonic epithelium directly. Subcutaneous injection disperses KPV systemically, which may not concentrate it at the intestinal mucosa in therapeutically relevant amounts. No comparative pharmacokinetic study between routes has been published.
The second common error is stability misinformation. Many guides say "store at room temperature before use." Lyophilized KPV is more stable at 4 degrees Celsius, away from moisture and UV light. Peptide bonds in small tripeptides like KPV are vulnerable to acid and oxidative hydrolysis. Heat accelerates both pathways. The rule is: refrigerate the powder, freeze for long-term storage (beyond 3 months), and never reconstitute until ready to use within the target window.
Reconstitution: Step-by-Step Math
Use bacteriostatic water, not sterile water for injection. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable life of the reconstituted vial to approximately 28 days at refrigerator temperature. Sterile water contains no preservative; once punctured, a vial reconstituted with sterile water should be used within hours or discarded, making multi-dose protocols impractical and risky.
Example calculation for a 1 mg vial:
| Goal | Bacteriostatic Water to Add | Resulting Concentration | Volume for 500 mcg dose |
|---|---|---|---|
| 1 mg/mL stock | 1.0 mL | 1000 mcg/mL | 0.50 mL |
| 2 mg/mL stock | 0.5 mL | 2000 mcg/mL | 0.25 mL |
Inject bacteriostatic water slowly down the inner glass wall, not directly onto the powder cake. Gently swirl, do not shake. Vigorous agitation creates bubbles that can denature peptide secondary structure and reduce potency.
KPV Peptide Injection Benefits: Honest Summary
The candidate benefits supported by preclinical evidence include: reduction of NF-kB-driven gut mucosal inflammation, reduced secretion of pro-inflammatory cytokines in stimulated immune cells, and potential wound-healing modulation via MC1R signaling in skin. These are mechanistically plausible and supported by animal data. None have been confirmed in a powered human RCT. The word "benefits" in this context means "findings in preclinical models that motivate human research," not confirmed clinical outcomes.
KPV vs. Alternatives: Honest Head-to-Head
| Compound | Mechanism | Strongest Evidence | Human Trial Data? | Where KPV Loses |
|---|---|---|---|---|
| KPV (injectable) | MC1R/MC3R agonism, NF-kB inhibition | Rodent colitis models | No RCT | No human dose established; injection may not be optimal route for gut effects |
| BPC-157 (injectable) | Multiple: VEGFR2, FAK, growth factor upregulation | Rodent healing models | No published RCT for injection | KPV loses on breadth of preclinical data volume; BPC-157 has larger published literature |
| Mesalamine (oral/rectal) | NF-kB inhibition, COX-2 suppression at colonic epithelium | Multiple Phase 3 RCTs in IBD | Yes, approved for UC | KPV loses completely on evidence level; mesalamine is the evidence-based standard |
| Budesonide (oral) | Glucocorticoid receptor, broad anti-inflammatory | Multiple Phase 3 RCTs | Yes, FDA approved | KPV loses on regulatory standing and evidence depth; budesonide has documented side effects but also documented efficacy |
| Alpha-MSH analogues (afamelanotide) | MC1R full agonist | Phase 3 RCT (EPP indication) | Yes, FDA approved (limited) | KPV loses as a partial pharmacological analog; afamelanotide has established human PK |
Operational Guide: Injection Technique and Site Rotation
Sites: Lower abdomen (at least 2 inches from the navel), outer thigh, or flank. Rotate clockwise through sites to avoid lipodystrophy from repeated injection at one location.
Syringe: Use an insulin syringe, 28 to 31 gauge, 0.5 inch needle. Draw the calculated volume. Tap out air bubbles and advance the plunger to the correct dose line before injecting.
Technique: Pinch a fold of skin. Insert the needle at approximately 45 degrees for individuals with less subcutaneous fat, or 90 degrees for those with more. Pull back the plunger slightly before injecting to confirm no blood return (indicates you are not in a vessel). Inject slowly, withdraw, and apply light pressure. Do not rub the site.
Timing: No confirmed data on optimal injection timing relative to meals or circadian rhythm for KPV. Research protocols vary. Morning administration is common in community research frameworks but is not evidence-based specifically for KPV.
Label Literacy: How to Read a KPV Certificate of Analysis
Any vial of KPV intended for injection research must be accompanied by a COA. Here is how to evaluate it.
| COA Field | What to Look For | Red Flag |
|---|---|---|
| Purity (HPLC) | At least 98% area under curve | Below 95% or method not stated |
| Identity (Mass Spec) | Confirmed MW near 327.4 Da (free acid) or correct salt form MW | MW absent or not confirmed by MS |
| Endotoxin (LAL test) | Below 1 EU/mg for injectable grade | No endotoxin test listed |
| Sterility | Tested or lyophilized in ISO Class 7 cleanroom minimum | No sterility statement |
| Lot Number | Matches label on your vial | Generic or missing lot number |
| Sequence confirmation | Lys-Pro-Val confirmed | Only brand name, no sequence |
A COA without mass spectrometry confirmation is essentially useless for identity verification. HPLC purity measures the ratio of your target peak to all peaks but cannot confirm what the target compound actually is. Demand both.
Side Effects and Contraindications
No controlled human safety database exists for KPV injection. Based on its mechanism, theoretical concerns include: melanocortin receptor cross-reactivity with the ACTH/adrenal axis (MC2R is expressed on adrenal cells, though KPV's binding affinity for MC2R is considered low relative to MC1R and MC3R), and potential effects on appetite via central melanocortin pathways at higher doses. Injection-site reactions (redness, minor swelling) are the most commonly reported anecdotal effects. Immunocompromised individuals, pregnant or breastfeeding persons, and those with adrenal insufficiency should not use this compound outside of medically supervised research contexts. Do not use if the reconstituted solution is not crystal clear.
FAQ
What is KPV peptide injection used for?
KPV is researched primarily for its anti-inflammatory properties, particularly in gut inflammation models. Preclinical data show it suppresses NF-kB signaling and reduces pro-inflammatory cytokines. Human clinical evidence is currently very limited.
What is the typical KPV peptide injection dose?
There is no established human clinical dose. Researchers working with subcutaneous KPV in animal models have used doses in the microgram-to-low-milligram per kilogram range. Human protocols circulating in research communities typically reference 0.5 to 1 mg per day, but this lacks RCT support.
How do you reconstitute KPV for injection?
Add bacteriostatic water (not sterile water) to the lyophilized vial using a fresh insulin syringe. A common research reconstitution is 1 mL bacteriostatic water per 1 mg peptide, yielding 1 mg/mL or 1000 mcg/mL. Calculate your target dose volume from that concentration.
Where is the KPV injection administered?
Subcutaneous injection into the lower abdomen, outer thigh, or flank is the standard research administration route. Rotate sites with each injection. Inject at roughly a 45-degree angle with an insulin syringe, pulling back gently to confirm no blood return.
How should reconstituted KPV be stored?
Reconstituted KPV with bacteriostatic water should be stored at 2 to 8 degrees Celsius (standard refrigerator) and generally used within 4 weeks. Lyophilized powder should be kept at 4 degrees Celsius away from light and moisture until use.
What is the mechanism of action of KPV?
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-MSH. It binds melanocortin receptors MC1R and MC3R and inhibits NF-kB nuclear translocation, reducing transcription of TNF-alpha, IL-6, and IL-1beta. This mechanism is well-characterized in cell and animal studies.
Is KPV peptide injection FDA approved?
No. KPV is not FDA approved for any indication. It is classified as a research compound. It is not legal to market for human use, and its safety and efficacy in humans have not been established through Phase 2 or Phase 3 clinical trials.
How does KPV compare to oral KPV or topical formats?
Preclinical gut-inflammation data actually favor oral or nanoparticle-encapsulated KPV for colitis models because the target tissue is the intestinal epithelium. Subcutaneous injection achieves systemic exposure but may not be the optimal route for gut-specific effects.
What are the side effects of KPV peptide injection?
No controlled human safety data exist. Reported anecdotal effects include mild injection site redness and transient fatigue. Because KPV acts on melanocortin receptors shared with the ACTH pathway, theoretical adrenal effects exist, though they have not been characterized in humans.
What does a degraded KPV vial look like?
Lyophilized KPV should be a white to off-white powder or cake. After reconstitution the solution should be clear and colorless. Cloudiness, visible particulates, or a yellow-brown tint indicate degradation or contamination; discard and do not inject.
Can KPV peptide injection be used with other peptides?
No formal interaction data exist. Some researchers combine KPV with BPC-157 based on overlapping gut-healing rationales. Because both act partly through anti-inflammatory pathways, additive or redundant effects are plausible but unconfirmed. Mixing in the same syringe is generally not recommended without verified compatibility data.
How do I read a KPV certificate of analysis?
Look for: purity above 98% by HPLC, correct molecular weight confirmation by mass spectrometry (MW 327.4 Da for the free acid form), sterility and endotoxin testing results, and a lot number that matches your vial label. Reject any COA without mass spec confirmation.
Sources
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-853.
- Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.
- Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29.
- Getting SJ. Targeting melanocortin receptors as potential novel anti-inflammatory therapies. Pharmacol Ther. 2006;111(1):1-15.
- United States Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP-NF.
- Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.
Footer Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation.
Research Compound: KPV is an unscheduled research compound not approved by the FDA or any equivalent regulatory agency for human therapeutic use. It is sold for laboratory and research purposes only.
Results: Outcomes described on this page reflect preclinical (animal and cell) research findings and do not represent guaranteed or expected results in humans. Individual responses, if any, will vary.
Trademark: All trademarks, product names, and brand names referenced are the property of their respective owners and are used for informational identification only. FormBlends has no affiliation with referenced research institutions or pharmaceutical manufacturers.